Leczenie stwardnienia rozsianego u kobiet ciężarnych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2013
Słowa kluczowe:
stwardnienie rozsiane, ciąża, farmakoterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Stwardnienie rozsiane występuje zwykle u młodych dorosłych, przede wszystkim płci żeńskiej. Wiele publikacji wskazuje na zwiększanie liczby nowych przypadków choroby, głównie w grupie młodych kobiet. W związku z coraz powszechniejszym dostępem do leczenia immunomodulującego (interferony, octan glatirameru) oraz wprowadzaniem na rynek nowych leków pojawia się pytanie: czy farmakoterapia może i powinna być kontynuowana w okresie ciąży i karmienia piersią? W artykule przedstawiono dane dotyczące bezpieczeństwa i ewentualnych zagrożeń związanych ze stosowaniem leków u kobiet ciężarnych ze stwardnieniem rozsianym oraz zalecenia i opinie ekspertów.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Alonso A., Hernan M.A.: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008; 71(2): 129-135.
2. Elhami S.R., Mohammad K., Sahraian M.A. et al.: A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Teheran, Iran: a population-based study. Neuroepidemiology 2011; 36(3): 141-147.
3. Myhr K.M., Mellgren S.I.: Corticosteroids in the treatment of multiple sclerosis. Acta Neurol. Scand. 2009; 189: 73-80.
4. Burton J.M., O’Connor P.W., Hohol M., Beyene J.: Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst. Rev. 2012; 12: CD006921.
5. Schardein J.L.: Chemically induced birth defects. Marcel Dekker Inc., New York 1993; 1(40): 307-313.
6. Gur Ch., Diav-Citrin O., Shechtman S. et al.: Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod. Toxicol. 2004; 18: 93-101.
7. Hoffman L.A., Kumpfel T., Heer I. et al.: Pregnancy and immunomodulatory therapy in multiple sclerosis patients. Nervenarzt 2006; 77: 663-668: 670.
8. Hellwig K., Beste Ch., Schimrigk S., Chan A.: Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther. Adv. Neurol. Dis. 2009; 2(1): 7-11.
9. Fragoso Y.D., Boggild M., Macias-Islas M.A. et al.: The effects of long-term exposure to disease modyfing drugs during pregnancy in multiple sclerosis. Clin. Neurol. Neurosurg. 2013; 115: 154-159.
10. Lu E., Wang B.W., Guimond C. et al.: Disease-modyfing drugs for multiple sclerosis in pregnancy. A systematic review. Neurology 2012; 79: 1130-1135.
11. Tsui A., Lee M.A.: Multiple sclerosis and pregnancy. Curr. Opin. Obstet. Gynecol. 2011; 23(6): 435-439.
12. Sandberg-Wollheim M., Frank D., Giesser B. et al.: Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806.
13. Boscovic R., Wande R., Wolpin J. et al.: The reproductive effects of interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807-811.
14. Amato M.P., Portaccio E., Ghezzi A. et al.: Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 2010; 75(20): 1794-1802.
15. Sandberg-Wollheim M., Alteri E., Moraga M.S., Kornmann G.: Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult. Scler. 2011; 17(4): 423-430.
16. Hellwig K., Gold R.: Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J. Neurol. 2011; 258: 502-503.
17. Bartosik-Psujek H.: Ciąża i poród u chorych na stwardnienie rozsiane. NeuroRaport 2012; 1(1): 10-13.
18. De Santis M., Straface G., Cavaliere A.F. et al.: The first case of mitoksantron exposure in early pregnancy. Neurotoxicol. 2007; 28(3): 696-697.
19. Hellwig K., Schimrigk S., Chan A., Epplen J., Gold R.: A newborn with Pierre Robin sequence after preconceptional mitoksantron exposure of a female with multiple sclerosis. J. Neurol. Sci. 2011; 307(1-2): 164-165.
20. Sanofi Aventis US. Aubagio® (teriflunomid) [online].
21. Fragoso Y.D., Finkelsztejn A., Kaimen-Maciel D.R. et al.: Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective multicenter case series. CNS Drugs 2010; 24(11): 969-976.
22. Lu E., Wang B.W., Guimond C., Synnes A. et al.: Safety of disease-modyfing drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp. Rev. 2013; 13(3): 251-260.
23. De Seze J., Chapelotte M., Delalande S. et al.: Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult. Scler. 2011; 10: 596-597.
24. Hellwig K., Beste Ch., Schimrigk S., Chan A.: Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther. Adv. Neurol. Disord. 2009; 2(1): 7-11.
2. Elhami S.R., Mohammad K., Sahraian M.A. et al.: A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Teheran, Iran: a population-based study. Neuroepidemiology 2011; 36(3): 141-147.
3. Myhr K.M., Mellgren S.I.: Corticosteroids in the treatment of multiple sclerosis. Acta Neurol. Scand. 2009; 189: 73-80.
4. Burton J.M., O’Connor P.W., Hohol M., Beyene J.: Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst. Rev. 2012; 12: CD006921.
5. Schardein J.L.: Chemically induced birth defects. Marcel Dekker Inc., New York 1993; 1(40): 307-313.
6. Gur Ch., Diav-Citrin O., Shechtman S. et al.: Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod. Toxicol. 2004; 18: 93-101.
7. Hoffman L.A., Kumpfel T., Heer I. et al.: Pregnancy and immunomodulatory therapy in multiple sclerosis patients. Nervenarzt 2006; 77: 663-668: 670.
8. Hellwig K., Beste Ch., Schimrigk S., Chan A.: Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther. Adv. Neurol. Dis. 2009; 2(1): 7-11.
9. Fragoso Y.D., Boggild M., Macias-Islas M.A. et al.: The effects of long-term exposure to disease modyfing drugs during pregnancy in multiple sclerosis. Clin. Neurol. Neurosurg. 2013; 115: 154-159.
10. Lu E., Wang B.W., Guimond C. et al.: Disease-modyfing drugs for multiple sclerosis in pregnancy. A systematic review. Neurology 2012; 79: 1130-1135.
11. Tsui A., Lee M.A.: Multiple sclerosis and pregnancy. Curr. Opin. Obstet. Gynecol. 2011; 23(6): 435-439.
12. Sandberg-Wollheim M., Frank D., Giesser B. et al.: Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806.
13. Boscovic R., Wande R., Wolpin J. et al.: The reproductive effects of interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807-811.
14. Amato M.P., Portaccio E., Ghezzi A. et al.: Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology 2010; 75(20): 1794-1802.
15. Sandberg-Wollheim M., Alteri E., Moraga M.S., Kornmann G.: Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult. Scler. 2011; 17(4): 423-430.
16. Hellwig K., Gold R.: Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J. Neurol. 2011; 258: 502-503.
17. Bartosik-Psujek H.: Ciąża i poród u chorych na stwardnienie rozsiane. NeuroRaport 2012; 1(1): 10-13.
18. De Santis M., Straface G., Cavaliere A.F. et al.: The first case of mitoksantron exposure in early pregnancy. Neurotoxicol. 2007; 28(3): 696-697.
19. Hellwig K., Schimrigk S., Chan A., Epplen J., Gold R.: A newborn with Pierre Robin sequence after preconceptional mitoksantron exposure of a female with multiple sclerosis. J. Neurol. Sci. 2011; 307(1-2): 164-165.
20. Sanofi Aventis US. Aubagio® (teriflunomid) [online].
21. Fragoso Y.D., Finkelsztejn A., Kaimen-Maciel D.R. et al.: Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective multicenter case series. CNS Drugs 2010; 24(11): 969-976.
22. Lu E., Wang B.W., Guimond C., Synnes A. et al.: Safety of disease-modyfing drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp. Rev. 2013; 13(3): 251-260.
23. De Seze J., Chapelotte M., Delalande S. et al.: Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult. Scler. 2011; 10: 596-597.
24. Hellwig K., Beste Ch., Schimrigk S., Chan A.: Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther. Adv. Neurol. Disord. 2009; 2(1): 7-11.